Characteristic | ESL 1200 mg | ESL 1600 mg | Total |
---|---|---|---|
(n = 58) | (n = 114) | (n = 172) | |
Age, years; median (range) | 37.0 (16–60) | 35.5 (16–65) | 36.5 (16–65) |
Gender, male; n (%) | 31 (53.4) | 52 (45.6) | 83 (48.3) |
Race; n (%) | |||
White | 53 (91.4) | 107 (93.9) | 160 (93.0) |
Black or African American | 5 (8.6) | 1 (0.9) | 6 (3.5) |
Other | 0 | 6 (5.3) | 6 (3.5) |
Region; n (%) | |||
US | 15 (25.9) | 28 (24.6) | 43 (25.0) |
Non-US | 43 (74.1) | 86 (75.4) | 129 (75.0) |
BMI, kg/m2; median (range) | 25.6 (17–59) | 24.3 (17–51) | 24.7 (17–59) |
Maximum consecutive 2-day baseline seizure rate | |||
Mean ± SD | 2.2 ± 1.84 | 2.5 ± 1.46 | 2.4 ± 1.60 |
Maximum consecutive 28-day baseline seizure rate | |||
Mean ± SD | 9.2 ± 6.72 | 11.1 ± 7.94 | 10.5 ± 7.59 |
Baseline AEDs used by ≥20% patients†; n (%) | |||
Carbamazepine | 22 (37.9) | 27 (23.7) | 49 (28.5) |
Valproic acid‡ | 12 (20.7) | 39 (34.2) | 51 (29.7) |
Number of AEDs at baseline†; n (%) | |||
1 | 41 (70.7) | 70 (61.4) | 111 (64.5) |
2 | 17 (29.3) | 44 (38.6) | 61 (35.5) |